Todd D. Cohen

Urology

12610 N Community House Rd Ste 100
Charlotte, NC 28277

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer.

Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer.

Journal: JCO precision oncology

Published: May 15, 2024

Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.

Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.

Journal: Prostate cancer and prostatic diseases

Published: December 20, 2023

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: November 09, 2022

Cell Cycle Progression Score, but Not Phosphatase and Tensin Homolog Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-risk Prostate Cancer in Men Treated With and Without Salvage Radiotherapy.

Cell Cycle Progression Score, but Not Phosphatase and Tensin Homolog Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-risk Prostate Cancer in Men Treated With and Without Salvage Radiotherapy.

Journal: The Journal of urology

Published: August 25, 2022

Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer.

Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer.

Journal: Biomarkers in medicine

Published: March 24, 2022

Hereditary cancer risk assessment and genetic testing in the community urology practice setting.

Hereditary cancer risk assessment and genetic testing in the community urology practice setting.

Journal: The Prostate

Published: November 15, 2021

Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy.

Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy.

Journal: Cancer reports (Hoboken, N.J.)

Published: May 14, 2021

The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.

The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.

Journal: International journal of radiation oncology, biology, physics

Published: April 12, 2021

Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy.

Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy.

Journal: Clinical genitourinary cancer

Published: October 13, 2020

Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.

Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.

Journal: The Prostate

Published: August 06, 2020

Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.

Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.

Journal: Urologic oncology

Published: July 17, 2020

Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score.

Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score.

Journal: Personalized medicine

Published: September 05, 2019

Showing 1-12 of 15

Last Updated: 09/26/2026